🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting over 82 million instances each year. Particularly high rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the face of rising global incidence, escalating drug resistance and the highly restricted available drugs currently available.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This milestone represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Data and Global Access

As per findings released by a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This puts it on an similar efficacy with the typical regimen, which uses an injection and a pill. The study included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Medical professionals treating patients have expressed positive views. Access to a one-pill regimen of this kind is described as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the disease for individuals and to prevent the spread of untreatable gonorrhoea globally.